Skip to main content

Table 3 Univariate analysis of postoperative complications

From: Relationship between gender and perioperative clinical features in lung cancer patients who underwent VATS lobectomy

Characteristic

Postoperative complications

Wald

P

OR

95% CI

NO(n = 252)

YES(n = 86)

Sexuality/case

  

14.83

<0.001

2.794

(1.656–4.712)

female

138

26

    

male

114

60

    

age/case

  

2.427

0.119

1.48

(0.904–2.424)

≤ 57y

133

37

    

>57y

119

49

    

BSA/case

  

0.996

0.318

1.284

(0.786–2.099)

≤ 1.64m2

130

39

    

>1.64m2

122

47

    

smoking history/case

  

14.21

<0.001

2.619

(1.587–4.32)

no

170

38

    

yes

82

48

    

chronic alcohol consumption /case

  

6.333

0.12

1.934

(1.157–3.233)

no

186

51

    

yes

66

35

    

hypertension/case

  

4.818

0.028

1.885

(1.070–3.321)

no

207

61

    

yes

45

25

    

FEVI/case

  

6.854

0.009

0.511

(0.309–0.845)

≤ 2.00

75

39

    

>2.00

177

47

    

FEV1 Pre / Ref

  

8.792

0.003

0.466

(0.281–0.772)

/case

      

≤ 92%

114

55

    

>92%

138

31

    

FEV1/FVC%/case

  

3.036

0.081

0.644

(0.393–1.056)

≤ 86.81%

119

50

    

>86.81%

133

36

    

tumor diameter/case

  

11.12

0.001

2.366

(1.426–3.924)

≤ 2.10

129

28

    

>2.10

123

58

    

tumor composition/case

 

5.244

0.022

1.798

(1.088–2.971)

ground-glass

130

32

    

solid

122

54

    

tumor type/case

  

4.749

0.029

2.022

(1.073–3.808)

AD

221

67

    

non-AD

31

19

    

T stage/case

  

13.59

<0.001

2.571

(1.556–4.247)

0–1

158

34

    

≥ 2

94

52

    

N stage/case

  

8.63

0.003

2.767

(1.403–5.458)

0

230

68

    

1,2

22

18

    

clinical staging /case

  

13.8

<0.001

2.522

(1.600-4.569)

MIS-I

199

50

    

II-III

53

36

    

operation time

  

3.976

0.046

1.655

(1.009–2.714)

≤ 112

137

36

    

>112

115

50

    

number of lymph nodes /case

 

9.538

0.002

2.218

(1.338–3.676)

≤ 10

140

31

    

>10

112

55

    
  1. BSA, body surface area. BMI, body mass index. AD, adenocarcinoma. classification as T stage and N stage according to the TNM system and clinical staging